LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs. The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina. Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition. "This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans. "In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is … Continue reading →

Stem Cell Therapy for Heart Disease Experts Launch Educational Resource for Cardiologists with Questions Answered by Dr. Howard Walpole FREEPORT, The Bahamas (PRWEB) March 11, 2013 I believe we have created a much needed go-to resource that will be of great use to cardiologists and other healthcare providers, said Brian Jenkins, Executive Multimedia Editor of Elsevier Multimedia Publishing in New York, NY, which runs the site for the AJC. The stem cell resource center provides a wealth of information on a burgeoning area in cardiology. Readers will find multiple educational opportunities: a thought leader roundtable video that allows you to select questions and get answers on topics of greatest interest; open access article content; news feeds on stem cell therapy; and the ability to submit questions to a leading expert, Dr. Walpole. The AJC wanted to do this resource center because cell therapy is an entirely new approach to treating serious cardiac diseases for which we have no good treatment in their advanced stages, said Vincent Friedewald, MD, FACC, an Associate Editor of the AJC, as well as Clinical Professor of Medicine at University of Texas Health Science Center in Houston, TX, and Adjunct Senior Research Professor at Indiana University … Continue reading →